IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

Bernard S. GREEN et al

Serial No.:

10/671,538

Filed:

29-Sep-2003

For:

MOLECULARLY IMPRINTED POLYMERS FOR

THE TREATMENT AND DIAGNOSIS OF MEDICAL

CONDITIONS

Examiner:

ROGERS, JAMES WILLIAM

Mail Stop Commitment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 *\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$\$*

Group Art Unit: 1618

Attorney

Docket: 26883

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Supplemental Information Disclosure Statement is being filed subsequent to an Office Action being mailed and a late fee of \$180 is due. Please charge my Deposit Account 50-1407 for this fee, as well as any additional fees due.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

> 09/08/2006 HBERHE 00000008 501407 10671538

Martin D. Movnihan

Registration No. 40,338

Dated: August 16, 2006

SEP 0 6 7006

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 in and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known			
				Application Number		71,538	
				Filing Date	Septe	ember 29, 2003	
				First Named Inventor Bernard S.C		ard S.GREEN et al	
(use as many sheets as necessary)					Art Unit	1618	
					Examiner Name	ROGERS, JAMES WILLIAM	
Sheet 1 of 3					Attorney Docket Number	26883	
12011			U.S.	PATENT	DOCUMENTS	ı	
Examiner Initials*	Cite No. 1	Document Number Number-Kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY 01-12-1999 11-28-1978 05-5-1992		Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-5,858,296			Domb		
	2	US-4,127,730			Wulff et al.		
	3	US-5,110,833			Mosbach		
	4	US-5,587,273	12-24-1	996	Yan et al.		
	5	US-5,589,358	12-31-1	996	Dawson		
	6	US-5,630,978	05-20-1	997	Domb		
	7	US-5,631,138	05-20-1	997	Kano et al.		
	8	US-5,872,198	02-16-1	999	Mosbach et al.		
	9	US-5,945,411	08-31-1999		Larson et al.		
	10	US-5,976,811	02-2-19	99	Müllner et al.		
				-			
						<u> </u>	
		-					
	1	1	1		1		1

		FOREIGN	PATENT DOCU	MENTS	·	
Examiner Initials*	Cite No. 1	Foreign Patent Documents Country Code ³ - Number ⁴ - Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
Examine Signatur			1	Date Considered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031 . Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Considered

Under the Paperwork Reduction Act of 1995, no persons are required to respond to on unless it contains a valid OMB control number

Under the Paperw	ork Reduction	n Act of 1995, no persons are required to respond to a co	llection of								
	Su	bstitute for form 1449A/PTO			te if Known						
				Application Number 10/671,538							
I	NFOR	MATION DISCLOSURE	Filing Date	September 29, 2003 Bernard S.GREEN et al							
	TATE	MENT BY APPLICANT	First Named Inventor								
	JIAIL	MENT DI ATTECANI	Group Art Unit	1618							
	(use	as many sheets as necessary)		Examiner Name	ROGERS, J	AMES WILLIAM					
Sheet	2	Of	3	Attorney Docket Number	26883						
		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS									
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.									
	11	Haupt et al. "Plastic Antibodies: Development and Applications", TIBTECH, 16: 468-475, 1998.									
	12	Mayes et al. "Molecularly Imprinted Polymers: Useful Materials for Analytical Chemistry?", Trends in Analytical Chemistry, 16(6): 321-332, 1997.									
	13	Vlatakis et al. "Drug Assay Using Antibody Mimics Made by Molecular Imprinting",									
	13	Nature, 361: 645-647, 1993.	moody	ividines ividee by iviolectial	imprinting,						
	14	Nature, 361: 645-647, 1993. Kauer et al. "Composition and Concentration of Bile Acid Reflux Into the Esophagus									
	1-4	of Patients With Gastroesophageal R									
	15	Ochsenkühn et al. "Colonic Mucosal									
	13	Acid Levels", Cancer, 85: 1664-1669			oxycholic						
	16	Shirvani et al. "Cyclooxygenase 2 Ex									
		Adenocarcinoma: Ex Vivo Induction by Bile Salts and Acid Exposure",									
		Gastroenterology, 118: 487-496, 2000.									
	17	Theisen et al. "Suppression of Gastric Acid Secretion in Patients With									
		Gastroesophageal Reflux Disease Results in Gastric Bacterial Acids", Journal of									
	-	Gastrointestinal Surgery, 4: 50-54, 2000.									
	18	Kamano et al. "Ratio of Primary and Secondary Bile Acids in Feces: Possible Marker									
		for Colorectal Cancer?", Dis Colon Rectum, 42(5): 668-672, 1999. Abstract.									
	19	Nehra et al. "Toxic Bile Acids in Gastro-Oesophageal Reflux Disease: Influence of									
		Gastric Acidity", GUT, 44(5): 598-602, 1999. Abstract.									
	20	Shindo et al. "Omeprazole Induces Altered Bile Acid Metabolism", GUT, 42: 266-									
		271, 1998. Abstract.									
	21	Zhang et al. "Dihydroxy Bile Acids Activate the Transcription of Cyclooxygenase-									
		2", The Journal of Biological Chemis			•						
	22	Whitcombe et al. "A New Method for the Introduction of Recognition Site									
		Functionality Into Polymers Prepared by Molecular Imprinting: Synthesis and									
		Characterization of Polymeric Recep									
		Chemical Society, 117: 7105-7111, 1									
	23	Bayerdorffer et al. "Unconjugated Se			Patients						
		With Colorectal Adenomas", GUT, 3									
	24	Berr et al. "Disorders of Bile Acid M			Disease",						
		Journal of Clinical Investigation, 90(
	25	Bernstein et al. "A Bile Acid-Induce			Risk and						
		Associated Quality Control Studies",									
	26	Fuhrman et al. "Increased Uptake of									
		An Initial Enhanced LDL Receptor Activity and of A Further Progressive Oxidation									
		of LDL", Free Radic Biol Med, 23(1									
			•								

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Signature

^{*}EXAMINER: Initial if reference considered, whether of not citation is in conformance with MPEP 609. Draw line infrough citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for 2313 4150, DO NOT SEND FEES OR COMPLETED EXPANS TO THIS ADDRESS. U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (08-03) Approved for use through 06/30/2006. OMB 0651-0031 Approved for use unough 00/30/2000. Olvid Colling State of Commerce State of Commerce of C

Complete if Known

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Out attacks for form 4.440A/DTO	Complete if Known		
Substitute for form 1449A/PTO	Application Number	10/671,538	
INFORMATION DISCLOSURE	Filing Date	September 29, 2003	
	First Named Inventor	Bernard S.GREEN et al	
STATEMENT BY APPLICANT	Group Art Unit	1618	
(use as many sheets as necessary)	Examiner Name	ROGERS, JAMES WILI	

	(use as	many sheets as necessary)	Examiner Name	ROGERS, JAMES WILLIAM				
Sheet	3	Of	3 Attorney Docket Number	26883				
		OTHER PRIOR ART – NON I	PATENT LITERATURE DOC	UMENTS				
٠	27	Ljubuncic et al. "Effect of Deoxycholic Acid and Ursodeoxycholic Acid on Lipid Peroxidation in Cultured Macrophages", GUT, 39(3): 475-478, 1996. Abstract.						
	28	Low-Beer et al. "Colonic Bacterial Activity, Biliary Cholesterol Saturation, and Pathogenesis of Gallstones", Lancet, 2(8099): 1063-1065, 1978. Abstract.						
	29	Peiffer et al. "Differential Effects of Deoxycholic Acid on Proliferation of Neoplastic and Differentiation Colonocytes In Vitro", Digestive Diseases and Sciences, 42(11): 2234-2240, 1997. Abstract.						
	30	Shoda et al. "Increase of Deoxycholate in Supersaturated Bile of Patients With Cholesterol Gallstone Disease and Its Correlation With De Novo Syntheses of Cholesterol and Bile Acids in Liver, Gallbladder Emptying, and Small Intestinal Transit", Hepatology, 21(5): 1291-1302, 1995. Abstract.						
	31	Fini et al. "Spectrophotometric Determination of Bile Acids. An Evaluation", Collection of the Czechoslovakian Chemical Communications, 58(1): 53-61, 1993. Abstract.						
	32	Wulff "Molecular Imprinting in Cross-Linked Materials With the Aid of Molecular Templates - A Way Towards Artificial Antibodies", Angewandte Chemie, International Edition, 34: 1812-1832, 1995. Abstract.						
Signature				Considered				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).

2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.